New study probes immune changes in bladder cancer before surgery
NCT ID NCT03978624
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) alone or with entinostat affects immune markers in people with muscle-invasive bladder cancer who cannot or choose not to have standard chemotherapy. Twenty participants receive the drugs before their scheduled bladder removal surgery. The goal is to measure changes in immune gene activity, not to treat the cancer directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda) and entinostat
What this could lead to
If successful, this study could reveal which immune markers predict better responses to these drugs, guiding future treatment for bladder cancer.
What could go wrong
This is a small, early-phase study focused on biological changes, not on curing or controlling the disease. Results may not lead to new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States